Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mesoblast

11.36
-0.5500-4.62%
Volume:54.53K
Turnover:618.22K
Market Cap:1.45B
PE:-12.31
High:11.51
Open:11.50
Low:11.03
Close:11.91
Loading ...

Mesoblast Plans to Double Transplant Centers Onboarded for Graft Versus Host Disease Treatment

MT Newswires Live
·
Yesterday

Mesoblast Expands U.S. Market with Ryoncil® Launch and Advances Other Therapies

TIPRANKS
·
Yesterday

Press Release: Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Dow Jones
·
Yesterday

Press Release: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Dow Jones
·
29 Apr

Mesoblast Limited Announces Director’s Interest Change

TIPRANKS
·
24 Apr

Mesoblast Expands Payer Coverage for Ryoncil

MT Newswires Live
·
17 Apr

Mesoblast Expands Insurance Coverage for Ryoncil to 104 Million Lives in US

MT Newswires Live
·
17 Apr

Mesoblast Expands Ryoncil Coverage to Over 100 Million US Lives

TIPRANKS
·
17 Apr

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

GlobeNewswire
·
17 Apr

Mesoblast Limited Announces Cessation of Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Issues Over 8 Million New Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Announces Quotation of New Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Issues New Equity Securities Under Employee Incentive Scheme

TIPRANKS
·
14 Apr

Mesoblast Limited Issues New Equity Securities for Employee Incentive

TIPRANKS
·
08 Apr

Top broker says Mesoblast shares can rocket 100%

MotleyFool
·
08 Apr

Mesoblast Considers Ryoncil, Revascor to Be US-Origin Products

MT Newswires Live
·
04 Apr

HotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!

The Market Herald
·
04 Apr

Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025

The Market Herald
·
04 Apr

BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs

Reuters
·
04 Apr

Mesoblast Says Products Exempt From US Tariffs

MT Newswires Live
·
04 Apr